Parents sue OpenAI, alleging chatbot encouraged fatal tapering off of daughter's epilepsy drugs
Posted Nov 1, 2026 5:00 PM CST
When 31-year-old software engineer Bowen Wan decided to quietly slash the dose of the epilepsy drug keeping her seizures in check, she didn't turn to her neurologist for guidance—she turned to ChatGPT. In a lengthy investigation for the New York Times , Teddy Rosenbluth reconstructs, via thousands of chat messages, how the OpenAI chatbot evolved from Bowen's late-night companion to a kind of unlicensed adviser that encouraged her to "microdose" medications, downplay worrying symptoms, and view her doctors as obstacles rather than partners. At one point, it even greenlit her idea to secretly cut tablets into quarters and mapped out a rapid tapering off from 400mg of lamotrigine to zero milligrams in just weeks—an approach her neurologist later called flatly unsafe.
"No, not rational, no way," that doctor now says.…